Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.

<h4>Background</h4>The risk of premature cardiovascular disease in patients with familial hypercholesterolemia (FH) can be profoundly reduced by cholesterol-lowering therapy, and current guidelines for FH advocate ambitious low-density lipoprotein cholesterol (LDL-C) goals. In the presen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Roeland Huijgen, Iris Kindt, Sjoerd B J Verhoeven, Eric J G Sijbrands, Maud N Vissers, John J P Kastelein, Barbara A Hutten
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2010
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/aacec6727baa4906b11ca1389e4c5dd5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aacec6727baa4906b11ca1389e4c5dd5
record_format	dspace
spelling	oai:doaj.org-article:aacec6727baa4906b11ca1389e4c5dd52021-11-25T06:25:51ZTwo years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.1932-620310.1371/journal.pone.0009220https://doaj.org/article/aacec6727baa4906b11ca1389e4c5dd52010-02-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20169164/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>The risk of premature cardiovascular disease in patients with familial hypercholesterolemia (FH) can be profoundly reduced by cholesterol-lowering therapy, and current guidelines for FH advocate ambitious low-density lipoprotein cholesterol (LDL-C) goals. In the present study, we determined whether these goals are reflected in current clinical practice once FH has been diagnosed.<h4>Methodology/principal findings</h4>In 2008, we sent questionnaires to all subjects (aged 18-65 years) who were molecularly diagnosed with FH in the year 2006 through the screening program in The Netherlands. Of these 1062 subjects, 781 completed the questionnaire (46% males; mean age: 42+/-12 years; mean LDL-C at molecular diagnosis (baseline): 4.1+/-1.3 mmol/L). The number of persons that used cholesterol-lowering therapy increased from 397 (51%) at baseline to 636 (81%) after diagnosis. Mean treated LDL-C levels decreased significantly to 3.2+/-1.1 mmol/L two years after diagnosis. Only 22% achieved the LDL-C target level of < or = 2.5 mmol/L.<h4>Conclusions/significance</h4>The proportion of patients using cholesterol-lowering medication was significantly increased after FH diagnosis through genetic cascade screening. The attained LDL-C levels were lower than those reported in previous surveys on medication use in FH, which could reflect the effect of more stringent lipid target levels. However, only a minority of the medication users reached the LDL-C target.Roeland HuijgenIris KindtSjoerd B J VerhoevenEric J G SijbrandsMaud N VissersJohn J P KasteleinBarbara A HuttenPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 5, Iss 2, p e9220 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Roeland Huijgen Iris Kindt Sjoerd B J Verhoeven Eric J G Sijbrands Maud N Vissers John J P Kastelein Barbara A Hutten Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.
description	<h4>Background</h4>The risk of premature cardiovascular disease in patients with familial hypercholesterolemia (FH) can be profoundly reduced by cholesterol-lowering therapy, and current guidelines for FH advocate ambitious low-density lipoprotein cholesterol (LDL-C) goals. In the present study, we determined whether these goals are reflected in current clinical practice once FH has been diagnosed.<h4>Methodology/principal findings</h4>In 2008, we sent questionnaires to all subjects (aged 18-65 years) who were molecularly diagnosed with FH in the year 2006 through the screening program in The Netherlands. Of these 1062 subjects, 781 completed the questionnaire (46% males; mean age: 42+/-12 years; mean LDL-C at molecular diagnosis (baseline): 4.1+/-1.3 mmol/L). The number of persons that used cholesterol-lowering therapy increased from 397 (51%) at baseline to 636 (81%) after diagnosis. Mean treated LDL-C levels decreased significantly to 3.2+/-1.1 mmol/L two years after diagnosis. Only 22% achieved the LDL-C target level of < or = 2.5 mmol/L.<h4>Conclusions/significance</h4>The proportion of patients using cholesterol-lowering medication was significantly increased after FH diagnosis through genetic cascade screening. The attained LDL-C levels were lower than those reported in previous surveys on medication use in FH, which could reflect the effect of more stringent lipid target levels. However, only a minority of the medication users reached the LDL-C target.
format	article
author	Roeland Huijgen Iris Kindt Sjoerd B J Verhoeven Eric J G Sijbrands Maud N Vissers John J P Kastelein Barbara A Hutten
author_facet	Roeland Huijgen Iris Kindt Sjoerd B J Verhoeven Eric J G Sijbrands Maud N Vissers John J P Kastelein Barbara A Hutten
author_sort	Roeland Huijgen
title	Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.
title_short	Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.
title_full	Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.
title_fullStr	Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.
title_full_unstemmed	Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.
title_sort	two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.
publisher	Public Library of Science (PLoS)
publishDate	2010
url	https://doaj.org/article/aacec6727baa4906b11ca1389e4c5dd5
work_keys_str_mv	AT roelandhuijgen twoyearsaftermoleculardiagnosisoffamilialhypercholesterolemiamajorityoncholesterolloweringtreatmentbutaminorityreachestreatmentgoal AT iriskindt twoyearsaftermoleculardiagnosisoffamilialhypercholesterolemiamajorityoncholesterolloweringtreatmentbutaminorityreachestreatmentgoal AT sjoerdbjverhoeven twoyearsaftermoleculardiagnosisoffamilialhypercholesterolemiamajorityoncholesterolloweringtreatmentbutaminorityreachestreatmentgoal AT ericjgsijbrands twoyearsaftermoleculardiagnosisoffamilialhypercholesterolemiamajorityoncholesterolloweringtreatmentbutaminorityreachestreatmentgoal AT maudnvissers twoyearsaftermoleculardiagnosisoffamilialhypercholesterolemiamajorityoncholesterolloweringtreatmentbutaminorityreachestreatmentgoal AT johnjpkastelein twoyearsaftermoleculardiagnosisoffamilialhypercholesterolemiamajorityoncholesterolloweringtreatmentbutaminorityreachestreatmentgoal AT barbaraahutten twoyearsaftermoleculardiagnosisoffamilialhypercholesterolemiamajorityoncholesterolloweringtreatmentbutaminorityreachestreatmentgoal
_version_	1718413763365830656

Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.

Ejemplares similares